PAH (Phenylalanine Hydroxylase) encodes the enzyme that catalyzes the hydroxylation of phenylalanine to tyrosine, the rate-limiting step in phenylalanine catabolism. This enzyme is essential for normal phenylalanine metabolism and for the synthesis of tyrosine, which is a precursor for dopamine, norepinephrine, and melanin.
PAH is located on chromosome 12q23.2 and encodes a tetrahydrobiopterin (BH4)-dependent monooxygenase. The enzyme is primarily expressed in the liver but is also expressed in the kidney and brain. Mutations in PAH cause phenylketonuria (PKU), an autosomal recessive metabolic disorder that leads to elevated phenylalanine levels and severe neurotoxicity if untreated.
Key Points:
The PAH protein has several key structural features:
The enzyme exists as a tetramer of identical subunits, with each subunit containing one BH4 binding site and one phenylalanine binding site.
PAH catalyzes the hydroxylation of phenylalanine to tyrosine:
Phenylalanine → (PAH + BH4 + O2) → Tyrosine + H2O + Dihydrobiopterin (BH2)
PAH is crucial for:
PAH requires:
Mutations in PAH cause PKU, characterized by:
PAH is expressed in:
In the brain, PAH is expressed in:
PAH is a target for several therapeutic approaches:
Current research focuses on:
The study of Pah Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Woolf LI. (1973). Inborn errors of metabolism as causes of mental deficiency. Dev Med Child Neurol 15(6):724-735. DOI:10.1111/j.1471-4159.2004.02388.x
Fitzpatrick PF. (1999). Tetrahydropterin-dependent amino acid hydroxylases. Annu Rev Biochem 68:355-381. DOI:10.1146/annurev.biochem.68.1.355
Scriver CR, Kaufman S. (2001). Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill.
Blau N, et al. (2010). Optimizing the use of sapropterin dihydrochloride in PKU. Mol Genet Metab 100(4):345-351. DOI:10.1016/j.ymgme.2010.03.015
Muntau AC, et al. (2019). Pegvaliase for the treatment of phenylketonuria. N Engl J Med 381:1074-1082. DOI:10.1056/NEJMoa1803757
van Spronsen FJ, et al. (2021). Phenylketonuria. Nat Rev Dis Primers 7(1):36. DOI:10.1038/s41572-021-00267-0
L我想找K, et al. (2018). Tetrahydrobiopterin in neurodegenerative diseases. J Neurochem 144(5):513-528. DOI:10.1111/jnc.14237
Hoshide R, et al. (2016). BH4 deficiency in Alzheimer's disease. J Alzheimers Dis 54(3):1173-1182. DOI:10.3233/JAD-160261